Is Hybrid Operating Room Necessary for Safe TAVR

According to this sub-study of the FRANCE TAVI registry, mortality is similar for transcatheter aortic valve replacement in hybrid operating rooms vs. conventional catheterization labs. These findings support performing TAVR in conventional cath labs, which goes hand in hand with TAVR expansion, with improved logistics and organization costs.

This study compared outcomes of patients undergoing TAVR in conventional cath labs vs. TAVR in hybrid ORs. The latter sounds ideal should complications arise, but hybrid ORs are scarce, costly and they involve a complicated logistic that might not be worth the while. A hybrid operating room does not make much sense without a cardiovascular surgeon in hand, and surgeons always have assistants, surgical technologists, attendings, etc., hence the complicated logistic, which in turn entails higher costs.

 

Indeed, for TAVR, as opposed to PCI, there should be heart surgery backup.


Read also: Promising Results for Tricuspid Repair.


All TAVR procedures done in 48 centers in France between January 2013 and December 2015 were retrospectively included in the France TAVI registry (French Transcatheter Aortic Valve Implantation). Primary end point was all cause mortality at one year. 30-day and 3-year mortality were considered secondary end points.

 

A total 12121 patients were included in the study, 62% received the procedure in conventional cath labs and 38% in Hybrid ORs. Baseline characteristics were similar between the groups.

 

Both groups showed a similar complications rate, below 2%. After multiple adjustments, major bleeding and infections were higher in the hybrid OR group (bleeding 6.3% vs. 4.8%; infections 6.1% vs. 3.5%; p<0.05), surprisingly, since we would expect exactly the opposite as regards infections.


Read also: Angiography Guided CABG Still Adequate.


Adjusted mortality at 1 and 3 years did not result different between the groups (cath lab 16.2% vs. hybrid OR 15.8% at 1 year, p=0.91 and 38.4%; vs 36.4%, p=0.49 at 3 years, respectively).

 

Conclusion

Mortality at 1 and 3 years is similar between patients undergoing TAVR in a conventional cath lab vs. a hybrid OR.

 

Título original: Transcatheter Aortic Valve Replacement in the Catheterization Laboratory Versus Hybrid Operating Room. Insights from the FRANCE TAVI Registry.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACC 2026 | STEMI-Door To Unload: Unloading with Impella before PCI did not reduce infarct size in anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI) remains associated with a high incidence of heart failure and mortality, even in the era of early reperfusion....

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...